CDP-Choline (Citicoline) for Attention

Verdict: Weak, mostly industry-backed evidence for attention

Citicoline (CDP-choline) shows only weak, preliminary signals for improving attention in healthy people, drawn from a handful of small studies. The largest, highest-quality trial found no cognitive benefit, so any real-world effect remains unproven.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is Weak (Tier C) because the supporting evidence is thin and low-quality. Three small randomized trials reported attention or processing-speed gains: one in 60 healthy women, one in 75 adolescent males (PMID 26179181), and one using a citicoline-plus-caffeine beverage in 60 adults (PMID 25046515). All were rated low quality, none reported p-values or effect sizes in their abstracts, two were funded by the supplement maker (Cognizin/Kyowa Hakko), and the caffeine combination makes it impossible to credit citicoline alone.

Crucially, the one large, high-quality, government-funded trial pulls the other way. COBRIT (n=1,213; PMID 23168823) tested 2,000 mg/day in traumatic brain injury patients and found no improvement in functional or cognitive status versus placebo. That negative result, in a far larger sample, weighs against strong attention claims even though the population differs from healthy users.

Authorities offer no endorsement. The US FDA treats citicoline as a supplement ingredient and has issued warning letters over disease claims, while EFSA in Europe rejected health claims for memory and vision, citing insufficient evidence. Mayo Clinic and Harvard Health are neutral, Cleveland Clinic only notes it is a well-absorbed choline form, and no neurology or psychiatry society guideline recommends it for attention.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.52
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
65%
Broadly consistent
Evidence level
E5
Single large RCT (n≥500)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L2 PubMedPrimary literature
0.60
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.515
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women
PMID: 2012 RCT (double-blind) n = 60
— See PubMed for details
View on PubMed
The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males
PMID: 26179181 2019 RCT (double-blind) n = 75
Finding: Citicoline associated with improved motor speed and attentional accuracy in adolescent males; preliminary, p-values not in abstract.
🟠 Limited quality ⚠️ Industry-funded
View on PubMed
Improvements in concentration, working memory and sustained attention following citicoline-caffeine beverage
PMID: 25046515 2014 RCT (double-blind) n = 60
Finding: Beverage group showed faster reaction times, fewer go/no-go errors, and higher P450 amplitudes; p-values not in abstract.
🟠 Limited quality Government
View on PubMed
Effect of citicoline on functional and cognitive status in traumatic brain injury (COBRIT)
PMID: 23168823 2012 RCT (double-blind) n = 1,213
Finding: Citicoline did not improve functional or cognitive status vs placebo in TBI patients (no significant difference).
🟢 High quality Government
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
L4d TW TFDA / 衛福部
Cautious
胞磷膽鹼 (Citicoline) 在台灣以西藥許可證列管,屬腦循環代謝改善劑類處方藥 (如尼可林 Nicholin 胞磷膽鹼鈉注射液),適應症為急性頭部外傷及腦部手術後之意識障礙;須憑醫師處方使用。 source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-attention-INT-cdp-choline-001 繁體中文版 →